Patients must have discontinued steroids >=  week prior to registration to Step  and remain off steroids thereafter, except as permitted (see below); patients with glioblastoma (GBM) must have been on stable dose of steroids, or be off steroids, for one week prior to registration to treatment (Step , , , )\r\n* NOTE: The following steroids are permitted (low dose steroid use is defined as prednisone  mg daily or less, or bioequivalent dose of other corticosteroid):\r\n** Temporary steroid use for computed tomography (CT) imaging in setting of contrast allergy\r\n** Low dose steroid use for appetite\r\n** Chronic inhaled steroid use\r\n** Steroid injections for joint disease\r\n** Stable dose of replacement steroid for adrenal insufficiency or low doses for non-malignant disease\r\n** Topical steroid\r\n** Steroids required to manage toxicity related to study treatment, as described in the subprotocols\r\n** Steroids required as pre- or post-chemotherapy medication for acceptable intervening chemotherapy\r\n*** NOTE: Steroids must be completed alongside last dose of chemotherapy
Patients requiring chronic treatment with systemic steroid therapy, other than replacement-dose steroids in the setting of adrenal insufficiency. Topical, inhaled, nasal and ophthalmic steroids are not prohibited.
Requirement, at the time of study entry, for concurrent steroids >  mg/day of oral prednisone or the equivalent, except steroid inhaler, nasal spray or ophthalmic solution
Systemic steroid therapy (> mg daily prednisone or equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of study treatment (Note: topical, inhaled, nasal and ophthalmic steroids are not prohibited).
Participants requiring chronic treatment with systemic steroid therapy, other than replacement-dose steroids in the setting of adrenal insufficiency; topical, inhaled, nasal and ophthalmic steroids are allowed
Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment\r\n* Physiologic doses of steroids (e.g. =<  mg prednisone/day or equivalent) are allowed; topical, inhaled, nasal and ophthalmic steroids are allowed
The use of systemic glucocorticoids in excess of  mg/day equivalent of prednisone is permitted provided it is not for the treatment of GVHD (e.g. chronic obstructive pulmonary disease, anti-emetic, infusion reactions). The chronic use of topical, inhaled, and locally injected steroids is permitted
Steroid treatment within seven () days prior to study treatment. Patients that require intermittent use of bronchodilators, topical steroids or local steroid injections will not be excluded from the study. Patients who have been stabilized to  mg PO QD or less seven () days prior to study drug administration are allowed.
Exposure to any prior chemotherapy, steroid use, or other myeloma treatment within  days prior to first dose. Pts currently on long term steroids do not require any washout period. in addition, steroid use for spinal cord compression is permitted and does not require a washout period.
Patients receiving systemic chronic steroid therapy or any immunosuppressive therapy (? mg/day prednisone or equivalent). Topical, inhaled, nasal and ophthalmic steroids are allowed.
Immunosuppressive steroids within  months before first ZW dosing, except for chronic steroid doses of ? mg per day for adrenal insufficiency
Chronic administration (defined as daily or every other day for continuous use >  days) of systemic corticosteroids within  days of the first planned dose off PROSTVAC; use of inhaled steroids, nasal sprays, and topical creams for small body areas are allowed
All cancer therapy, including radiation, topical steroid, and chemotherapy, must have been discontinued at least  week or  half-lives whichever is the longest prior to treatment in this study; the only exceptions are participants who are symptomatic from their skin lesions and have been on corticosteroids for prolonged periods of time (>  days) without change may continue use of either systemic steroid (equivalent to =<  mg per day of prednisone) or topical steroids are eligible for this study if the frequency and dosage steroids has not changed for  days prior to the study; these participants should continue on the same dose of systemic/topical steroid throughout the study period unless they achieve a complete response at which time steroids can be discontinued\r\n* Patients are allowed to continue any medications with known activity in T cell lymphomas at the pre-enrollment doses for conditions other than T cell lymphomas (i.e., steroids for sarcoidosis), as long as there is evidence of T cell lymphoma progression while patients were on these agents
Is currently receiving oral steroid treatment (inhaled steroids are permitted)
Patients who are immunocompromised as follows: \r\n* Human immunodeficiency virus (HIV) positivity\r\n* Chronic administration (defined as daily or every other day for continued use >  days) of systemic corticosteroids or other immune suppressive drugs, within  days before treatment on study; nasal, or inhaled steroid, topical steroid creams and eye drops for small body areas are allowed\r\n* Patients who have undergone allogeneic peripheral stem cell transplantation, or solid organ transplantation requiring immuno-suppression\r\n** Active autoimmune disease, except patients with type  diabetes mellitus, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring current immuno-suppression, or with other endocrine disorders on replacement hormones or are not excluded if the condition is well controlled
All cancer therapy, including radiation, topical steroid, and chemotherapy must have been discontinued at least  week or  half-lives whichever is the longest prior to treatment in this study; the only exceptions are participants who are symptomatic from their skin lesions and have been on corticosteroids for prolonged periods of time (>  days) without change may continue use of either systemic steroids (equivalent to <  mg per day of prednisone) or topical steroids are eligible for this study if the frequency and dosage steroids has not changed for  days prior to the study; these participants should continue on the same dose of systemic/topical steroid throughout the study period unless they achieve a complete response at which time steroids can be discontinued; patients are allowed to continue any medications with known activity in T cell lymphomas at the pre-enrollment doses for conditions other than T cell lymphomas (ie, steroids for sarcoidosis), as long as there is evidence of T cell lymphoma progression while patients were on these agents
Stable disease (SD) for >= days, without steroid use (or stable steroid dose established for >= days before the first dose of TAK-).
Patients may not receive ?  mg of prednisone or equivalent between days - and + of UCART infusion. Hydrocortisone required for mineralocorticoid replacement therapy is authorized at all times as needed clinically. Topical, inhaled, or nasal route of steroids are permitted;
Patients may not receive ?  mg of prednisone or equivalent between days - and + of UCART infusion. Hydrocortisone required for mineralocorticoid replacement therapy is authorized at all times as needed clinically. Topical, inhaled, or nasal route of steroids are permitted;
Use of systemic chronic steroid therapy (?mg /day of prednisone or equivalent), or any immunosuppressive therapy within  days of first dose of study treatment. Topical, inhaled, nasal, or ophthalmic steroids are allowed.
Concurrent use of systemic steroids or steroid eye drops; this is to avoid immunosuppression which may lead to potential complications with vaccinia (priming vaccination); nasal, topical or inhaled steroid use is permitted
No systemic glucocorticoids will be permitted within  hours prior to study registration\r\n* Note: Topical steroids, bronchodilators and local steroid injections are permitted if clinically required
The use of corticosteroids to control cerebral edema or treat neurologic symptoms will not be allowed, and patients who previously required corticosteroids for symptom control must be off steroids for at least  weeks; low-dose steroid use (=<  mg of prednisone or equivalent) as corticosteroid replacement therapy is allowed
Steroids within  weeks prior to event , except:\r\n* =<  mg prednisone or equivalent per day\r\n* Steroid with little to no systemic absorption (ie, topical or inhaled steroids)
Chronic administration (defined as daily or every other day for continued use >  days) of corticosteroids deemed systemic by investigator within  days before the first planned dose of PROSTVAC; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowed
The use of corticosteroids to control cerebral edema or treat neurologic symptoms will not be allowed, and patients who previously required corticosteroids for symptom control must be off steroids for at least  weeks; low-dose steroid use (=<  mg of prednisone or equivalent) as corticosteroid replacement therapy is allowed
Require steroid therapy or steroid-containing compounds, or have used systemic steroids in the past  weeks, or have used topical or inhalational steroids in the past  weeks prior to lymphodepletion; the exception being patients on chronic physiologic dose of steroid (Turnstile II)
Requires no steroids within  weeks and have not used topical or inhalational steroids in the past  weeks prior to lymphodepletion; the exception being patients on chronic physiologic dose of steroid (Turnstile II)
Require steroid therapy or steroid-containing compounds, or have used systemic steroids in the past  days, or have used topical or inhalational steroids in the past  weeks prior to lymphodepletion; Exception: patients on physiologic dose of steroid (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)
Concurrent need of use of corticosteroids >  mg/day of oral prednisone or the equivalent, except topical preparations (e.g., topical creams, steroid inhaler, nasal spray or ophthalmic solution);
Systemic chronic steroid therapy (? mg/day prednisone or equivalent) or any immunosuppressive therapy  days prior to planned date for first dose of study treatment. Topical, inhaled, nasal and ophthalmic steroids are allowed.
Subjects on chronic steroid therapy >  mg/day within  weeks of screening except for inhaled, nasal, or topical steroids
? weeks for topical therapy (including steroids, retinoids, nitrogen mustard or imiquimod) Topical steroids (maximum strength: medium potency) and oral steroids (? mg prednisone equivalent/day) are allowed, if the patient has been on a stable dose with stable symptoms for at least  weeks prior to study entry.
Concomitant corticosteroid use, systemic or topical, for treatment of skin disease. However, topical steroids (maximum strength: medium potency) and oral steroids (? mg prednisone equivalent/day) are allowed, if patient has been on a stable dose with stable symptoms for at least  weeks prior to study entry.
Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (e.g., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least  weeks prior to randomization are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study
Previous autoimmune complication from PD- or PD-L requiring discontinuation of therapy or treatment with steroids (ongoing treatment with more than  mg of prednisone or steroid equivalent daily, excluding inhaled or topical steroids).
Concurrent systemic immunosuppressive therapy or steroid therapy with more than  consecutive days of steroids within the last  weeks except in association with preparative regimen and NK cell infusion-inhaled corticosteroids is permitted
Steroid therapy, or steroid therapy with more than  consecutive days of steroids within the prior  weeks \r\n* The use of prednisone or equivalent < . mg/kg/day (absolute maximum of  mg/day) as replacement therapy is permitted\r\n* Inhaled or topical corticosteroids are permitted
Systemic steroid therapy or steroid therapy that cannot be discontinued with more than  consecutive days of steroids within the prior  weeks\r\n* Note: the use of prednisone or equivalent < . mg/kg/day (absolute maximum of  mg/day) as replacement therapy is permitted; inhaled or topical corticosteroids are permitted
Patients who have received corticosteroids within  days prior registration are not eligible, UNLESS the patient has been taking a continuous dose of no more than  mg/day of prednisone for at least  month prior; NOTE: low dose steroid use for control of nausea and vomiting will be allowed; topical steroid use and inhaled steroids are also permitted
Concurrent treatment with immunosuppressive or immunomodulatory agents, including any systemic steroid (exception: inhaled or topically applied steroids, and acute and chronic standard dose NSAIDs, are permitted). Use of a short course (i.e., ?  day) of a glucocorticoid is acceptable to prevent a reaction to the IV contrast used for CT scans.
Receipt of corticosteroids within  days prior to the first dose of study treatment, unless patient has been taking a continuous dose of no more than  mg/day of prednisone for at least  month prior to first dose of study treatment; low dose steroid use for the control of nausea and vomiting will be allowed; topical steroid use is permitted; inhaled steroids are permitted
Chronic administration (defined as daily or every other day for continued use >  days) of corticosteroids deemed systemic by investigator within  days before the first planned dose of PROSTVAC; use of inhaled steroids, nasal sprays, intra-articular injections and topical creams for small body areas is allowed
Current or prior use of immunosuppressive medication within  days before the first dose of MEDI (excluding intranasal, inhaled, topical steroids, or local steroid injections)
Receipt of corticosteroids within  days prior to the first dose of study treatment, unless patient has been taking a continuous dose of no more than  mg/day of prednisone for at least  month prior to first dose of study treatment; low dose steroid use for the control of nausea and vomiting will be allowed; topical steroid use is permitted; inhaled steroids are permitted
The recombinant vaccinia vaccine should not be administered if the following apply to either recipients or, for at least  weeks after vaccination, their close household contacts (close household contacts are those who share housing or have close physical contact):\r\n* Persons with active or a history of eczema or other eczematoid skin disorders\r\n* Those with other acute, chronic or exfoliative skin conditions (e.g., atopic dermatitis, burns, impetigo, varicella zoster, severe acne or other open rashes or wounds) until condition resolves\r\n* Pregnant or nursing women; children under  years of age\r\n* Patients should have no evidence, as listed below, of being immunocompromised:\r\n** HIV positivity \r\n** Hepatitis B or C positivity\r\n** Concurrent use of topical steroids (including steroid eye drops) or systemic steroids; nasal or inhaled steroid use is permitted
Participants may have had any number of previous hormonal therapies (antiandrogens, steroids, estrogens, finasteride, dutasteride, ketoconazole, abiraterone) provided these were discontinued >=  weeks before enrollment; participants on prednisone  mg daily or another equivalent steroid dose are eligible; participants on inhaled steroid are eligible
Chronic administration (defined as daily or every other day for continued use >  days) of corticosteroids deemed systemic by investigator within  days before the first planned dose of PSA-TRICOM; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowed
Patients who are immunocompromised as listed as follows:\r\n* Human immunodeficiency virus positivity\r\n* Chronic administration (defined as daily or every other day for continued use >  days) of systemic corticosteroids (including steroid eye drops) or other immune suppressive drugs, within  days before the first planned dose of PSA-TRICOM; nasal, or inhaled steroid, and topical steroid creams for small body areas are not excluded\r\n* Patients who have undergone allogeneic peripheral stem cell transplantation, or solid organ transplantation requiring immunosuppression \r\n* History of splenectomy
Patients on continuous steroid therapy for at least  hours (hrs) (or other continuous immunosuppressives such as azathioprine or cyclosporine A) are excluded on the basis of potential immune suppression; patients must have had  weeks of discontinuation of any continuous steroid therapy (taken for at least hrs duration) prior to enrollment (except steroids used for allergic reactions or as anti-emetics for systemic chemotherapy which are permitted)
Concomitant corticosteroid use for systemic or topical treatment of skin disease is not allowed except a dose of steroid of no more than  mg of prednisone or its equivalence is allowed for asthma, chronic obstructive pulmonary disease (COPD), or inflammatory bowel disease (IBD); stable use of topical corticosteroids of mid-potency will be allowed for patients with erythroderma-Sezary syndrome (T) and tumor stage (T) with intense pruritus
Use of systemic steroids within  days before the first dose of MEDI- (inhaled and topical corticosteroids are permitted). Subjects may take replacement doses of steroids (defined as ?  mg/day hydrocortisone or the equivalent) if on a stable dose for at least  weeks prior to the first dose of MEDI-. This does not include required steroid prophylaxis prior to the first infusion of MEDI-
Patients receiving corticosteroids at the time of the first vaccine, with the exception of nasal or inhaled steroid, at a dose above physiologic levels will be removed and replaced; for the purposes of this study, physiologic dose will be defined as <  mg of dexamethasone/day; once vaccinations have been initiated, if patients subsequently require increased steroids, they will still be permitted to remain on the study, but every effort will be made to minimize steroid requirements
steroids are currently not required and more than  days since last steroid treatment
Requirement for drugs, juices and/or herbs strongly inhibit CYPA from within  days prior to D of alisertib and throughout treatment; NOTE: glucocorticoids are considered inducers of CYPA; however, their use is allowed if patient has been taking a continuous dose of no more than  mg/day of prednisone (or its equivalent) for at least  month prior to D of alisertib; in addition, low dose steroid use for the control of nausea and vomiting will be allowed; topical steroid use and inhaled steroids are also permitted
No concurrent systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e. prednisone, dexamethasone), continuous use of topical steroid creams or ointments, or ophthalmologic steroids; if a subject is currently taking corticosteroids, treatment should be discontinued two weeks prior to starting protocol therapy; occasional use of steroid inhalers is allowed
Any steroid treatment except for that required for replacement therapy in adrenal insufficiency or inhaled steroids for the treatment of asthma
Any steroid treatment except for that required for replacement therapy in adrenal insufficiency, topical or injected testosterone for hypogonadism, or inhaled steroids for the treatment of asthma
Patients receiving steroids or immunosuppressive therapy for the improvement of hematological parameters (stable steroid treatment for adrenal failure or chronic medical conditions, and intermittent dexamethasone as antiemetics are allowed).
Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids or steroid inhalers
Concurrent use of corticosteroids (exception: nasal corticosteroids, inhaled steroids, adrenal replacement steroids and steroid creams are allowed)
Ongoing therapy with chronic or high dose corticosteroids. Low dose steroids (i.e. prednisone ?  mg or an equivalent steroid dose), inhaled and topical steroids are permitted
Requirement, at time of study entry, for concurrent steroids >  mg/day of oral prednisone or the equivalent, except steroid inhaler, nasal spray, or ophthalmic solution
Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids or steroid inhalers\r\n* If a patient had been taking steroids, at least  weeks must have passed since the last dose
Their neurological function is stable for at least  days and either off steroid therapy or on a stable steroid regimen.
Receipt of corticosteroids within  days prior to the first dose of study treatment, unless patient has been taking a continuous dose of no more than  mg/day of prednisone or equivalent for at least  month prior to first dose of study treatment; low dose steroid use for the control of nausea and vomiting, topical steroid use and inhaled steroids are permitted
History of steroid psychosis
Chronic oral or intravenous systemic steroid use (defined as being used on a regular basis or who have a problem that has required ongoing use of steroids in the last  days for greater than  days)
Recent steroid treatment within the last month
Chronic, current or recent (within the past three months) use of glucocorticoids (systemic, topical and/or nasal sprays or steroid topical creams to large body surface area); use of steroid topical creams for small body areas (=< % body surface) during study intervention is allowed
Chronic, current or recent (within the past  weeks) use of systemic steroid doses equivalent to prednisone >  mg daily for continued use >  days; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowed
Chronic administration (defined as daily or every other day for continued use >  days) of systemic glucocorticoids within  days of the first planned dose of PROSTVAC-V/F; use of inhaled steroids, nasal sprays, and all topical preparations (creams, solutions, gels, ointments, etc.) for up to % of the body surface area is allowed
Chronic administration (defined as daily or every other day for continued use >  days) of systemic corticosteroids within  days of the first planned dose of PROSTVAC-V/F; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowed
Any oral steroid use within  weeks of testing
Chronic administration of immunosuppressive agents or other immune-modifying drugs or chemotherapeutic agents within six months prior to the first vaccine dose; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowed
Require, at the time of study entry, treatment with steroids >  mg/day of oral prednisone (or equivalent), except topical use, steroid inhaler, nasal spray or ophthalmic solution
Patients on chronic therapy with any systemic immunosuppressant (not counting inhaled steroids or steroid creams) for any reason, including autoimmune disease
Subjects with asthma who require intermittent use of bronchodilators (such as albuterol) will not be excluded from this study. Inhaled steroids and intra-articular steroid injections are permitted in this study.
